Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 32 recruiting now early-phase tilt #100 of 28,707 conditions

Insulin Resistance: early-phase trial registry

32 of 122 indexed Insulin Resistance trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #100 of 28,707 conditions by registered trial count.

122 US clinical trials · 32 currently recruiting · #100 of 28,707 conditions by registered trial count

Insulin Resistance: 122 US clinical trials tracked, 32 recruiting.

Insulin Resistance is the subject of 122 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 7 of these trials.

Enrollment posture brief

Registry condition insulin-resistance

OPEN 32 | RECR 26% | LATE 10 | EARLY 22 | RANK #100 | SPON 7

Nearest open-share peer: Attention Deficit Hyperactivity Disorder (ADHD) (26% recruiting · 19 trials)

Renal Cell Carcinoma41%Advanced Cancer36.6%Ulcerative Colitis36.6%Insulin Resistance (this)26%Low Back Pain25.2%
Open-enrollment share among volume-matched conditions near Insulin Resistance

Insulin Resistance lists 32 open slots (26% of 122 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Insulin Resistance on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Insulin Resistance is recruiting below its size-band peers.

    32 of 122 indexed trials (26.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Insulin Resistance trials is spread across many organizations.

    Washington University School of Medicine accounts for 7 of 122 trials (5.7%). 72 distinct sponsors appear on at least one study for this condition label.

  3. Most Insulin Resistance trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 121 trials that report a genuine target (sentinel values excluded). 92 of those (76%) plan for fewer than 100 participants.

  4. Insulin Resistance research is mostly interventional.

    102 interventional and 20 observational studies make up this index (83.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 115Phase 27Phase 32Phase 48

Open and recent trials

122 total, page 3 of 3

COMPLETED NA 28 participants

Resveratrol and the Metabolic Syndrome

Rockefeller University

NCT01714102

COMPLETED 28 participants

Relative Sarcopenia and Cardiometabolic Risk in Young Adults With Obesity

Massachusetts General Hospital

NCT04195061

COMPLETED Phase 1 28 participants

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

Indiana University

NCT00871234

COMPLETED 27 participants

Mitochondrial Methylation in Type 2 Diabetes

University of Arizona

NCT04126551

COMPLETED Early Phase 1 25 participants

Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)

Pennington Biomedical Research Center

NCT02697201

COMPLETED NA 24 participants

Carnitine and Liver Mitochondria Fatty Acid Processing

Pennington Biomedical Research Center

NCT03193125

COMPLETED NA 23 participants

Insulin Resistance in Adolescents

University of Wisconsin, Madison

NCT04089332

COMPLETED NA 22 participants

Relation of Obesity With Frequency of Meals (MST 0557)

Rockefeller University

NCT00229255

COMPLETED 20 participants

Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.

University of Chicago

NCT00720889

COMPLETED NA 18 participants

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

Beth Israel Deaconess Medical Center

NCT00004419

COMPLETED NA 16 participants

Acute Exercise on Brain Insulin Sensitivity

Rutgers, The State University of New Jersey

NCT05853913

COMPLETED 16 participants

Production of Free Fatty Acids From Blood Triglycerides

Mayo Clinic

NCT00911482

COMPLETED NA 14 participants

Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents

Yale University

NCT01901978

COMPLETED Phase 2 14 participants

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Nick Giannoukakis, PhD

NCT02597101

COMPLETED NA 10 participants

Effects of Sleep Duration and Architecture on Insulin Sensitivity

University of California, San Francisco

NCT01396941

COMPLETED Early Phase 1 9 participants

Low Dose Fat-Induced Insulin Resistance

University of Pennsylvania

NCT03479671

COMPLETED Early Phase 1 9 participants

Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)

Pennington Biomedical Research Center

NCT01872533

COMPLETED NA 8 participants

Comparison of Time-Restricted Feeding Versus Grazing

Pennington Biomedical Research Center

NCT01895179

COMPLETED NA 8 participants

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

Washington University School of Medicine

NCT02706288

COMPLETED Phase 1 5 participants

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

Harbor Therapeutics

NCT00991107

COMPLETED NA 4 participants

Novel Therapies for Metabolic Complications of Lipodystrophies

University of Texas Southwestern Medical Center

NCT00457938

COMPLETED Phase 4

Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

University of Colorado, Denver

NCT00364221

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 15
Phase 2 7
Phase 3 2
Phase 4 8

Named interventions

Most-linked intervention names on Insulin Resistance records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Dietary supplement
5 trials
Placebo Drug
5 trials
Exercise Behavioral
4 trials
placebo Drug
4 trials
Metformin Drug
3 trials
Placebo Other
3 trials
rosiglitazone Drug
2 trials
pioglitazone Drug
2 trials

US sites by state

Facility locations filed on Insulin Resistance trials. A trial with sites in several states counts in each.

California 21 trials
Massachusetts 10 trials
Missouri 9 trials
New York 8 trials
Texas 7 trials
Pennsylvania 7 trials
Louisiana 7 trials
Minnesota 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Insulin Resistance page

122 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Insulin Resistance condition card totals 122 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.